OPN-51107

January 28, 2019 Publication

BET Inhibition Modifies Melanoma Infiltrating T Cells and Enhances Response to PD-L1 Blockade

AUTHORS Nikbakht, et al
Programs OPN-51107

https://doi.org/10.1016/j.jid.2018.12.024

January 31, 2018 Publication

BRD4 Profiling Identifies Critical Chronic Lymphocytic Leukemia Oncogenic Circuits and Reveals Sensitivity to PLX51107, a Novel Structurally Distinct BET Inhibitor

AUTHORS Ozer , et al
Programs OPN-51107

https://doi.org/10.1158/2159-8290.CD-17-0902

July 1, 2017 Poster

Resistance to BET inhibitors involves the Wnt/β-catenin Pathway in Uveal Melanoma

AUTHORS Ambrosini, et al
Programs OPN-51107

December 2, 2016 Poster

Response and Resistance to Bromodomain Inhibition in Acute Myeloid Leukemia

AUTHORS Huang, et al
Programs OPN-51107

July 15, 2016 Poster

Broad Anti-Tumor Activity of a Novel BET Bromodomain Inhibitor

AUTHORS Ma, et al
Programs OPN-51107

December 16, 2015 Presentation

A novel inhibitor of BET family bromodomains demonstrates in vivo and in vitro potency in B-cell malignancy

AUTHORS El-Gamal, et al
Programs OPN-51107

December 3, 2015 Poster

Efficacy and Mechanismof Action of the Novel Bromodomain Inhibitor, PLX51107, in B Cell Malignancies

AUTHORS Mead, et al
Programs OPN-51107

previous 1 2